BioSpace News Archive

The Prescription Drug User Fee Act (PDUFA) target action date for completion of the FDA review is March 21, 2019

Praxis Bioresearch announced that it has been awarded a Fast-Track Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH).

AXIM® Biotechnologies, Inc. announced positive results from stability and dissolution tests performed on its prime drug candidate, MedChew Rx®, which will undergo clinical trials for the treatment of pain and spasticity in Multiple Sclerosis (MS) patients.

CFN Media Group announces publication of an article covering Emerald Health Therapeutics Inc.'s (TSX-V: EMH) (OTCQX: EMHTF) recent acquisition of a dealer license from Abattis Bioceuticals Corp. that enables it to compete in emerging market verticals.

Lyme ImmunoBlots (IgM and IgG) represents quantum leap in test performance over the traditional B. burgdorferi Western blots.

Product Quest Manufacturing is voluntarily recalling Lot# 173089J of CVS Health 12 Hour Sinus Relief Nasal Mist, a clear, colorless liquid, to the consumer level. The product was found to have had microbiological contamination identified as Pseudomonas aeruginosa.

Space 2.0 Pioneer BridgeSat’s Leadership Expansion Promotes Company’s Growth and Development

Centinel Spine, LLC is pleased to announce that UnitedHealthcare®, the nation’s second largest commercial insurer, has issued a positive medical policy for Lumbar Total Disc Replacement (TDR).

The two abstracts compare U.S. neurologists’ self-reported perceptions with actual prescribing behavior to assess if the use of highly effective therapies as first-line treatment is increasing over time and what disease metrics and treatment expectations drive the selection of monoclonal antibody agents in patients recently switched to a new therapy

EnvoyAI, has entered into a distribution deal with Mach7 Technologies, a leading enterprise imaging solution provider.